BATS · ARKG
Financial Services · Asset Management
$48.16
Up+$0.29 (+0.61%)
Updated Oct 26, 2026, 5:24 AM
SID Score
5.0/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance · ARKG
1M range · 20 trading sessions · Daily adjusted prices
Prices through Oct 23, 2026
ARKG closed at $48.16 after 20 trading sessions, down 9.73% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 23, 2026 | $47.52 | $48.21 | $46.6757 | $48.16 | 3.63M |
| Oct 22, 2026 | $49.25 | $49.91 | $46.83 | $47.87 | 7.34M |
| Oct 21, 2026 | $48.62 | $50.38 | $48.35 | $49.85 | 4.32M |
| Oct 20, 2026 | $47.14 | $49.28 | $46.655 | $48.65 | 6.5M |
| Oct 19, 2026 | $47.25 | $48.34 | $46.72 | $47.37 | 4.13M |
| Oct 16, 2026 | $49.36 | $49.54 | $46.405 | $46.70 | 9.85M |
| Oct 15, 2026 | $47.33 | $49.91 | $46.62 | $49.24 | 8.96M |
| Oct 14, 2026 | $47.75 | $49.13 | $47.35 | $48.28 | 3.2M |
| Oct 13, 2026 | $49.10 | $49.29 | $48.072 | $48.51 | 3.92M |
| Oct 12, 2026 | $51.10 | $51.11 | $48.69 | $49.48 | 4.86M |
| Oct 9, 2026 | $49.76 | $52.08 | $49.62 | $51.30 | 5.8M |
| Oct 8, 2026 | $49.11 | $49.49 | $48.29 | $49.29 | 5.75M |
| Oct 7, 2026 | $50.61 | $51.8295 | $49.67 | $50.14 | 7.11M |
| Oct 6, 2026 | $57.77 | $58.83 | $51.54 | $51.75 | 14.27M |
| Oct 5, 2026 | $53.93 | $57.04 | $53.44 | $56.77 | 5.73M |
| Oct 2, 2026 | $53.89 | $54.78 | $53.10 | $54.00 | 3.03M |
| Oct 1, 2026 | $54.19 | $54.8665 | $53.04 | $53.17 | 3.88M |
| Sep 30, 2026 | $54.25 | $55.30 | $54.06 | $54.22 | 3.58M |
| Sep 29, 2026 | $53.62 | $54.95 | $53.03 | $53.95 | 3.59M |
| Sep 28, 2026 | $52.77 | $54.06 | $52.57 | $53.35 | 2.51M |
The latest Smart Investors Daily articles mentioning ARKG.
Company
Market Activity
Research & News
ARKG research
Company profile and research snapshot.
The fund is an actively-managed exchange-traded fund ("ETF") that will invest under normal circumstances primarily (at least 80% of its assets) in domestic and foreign equity securities of companies across multiple sectors, including healthcare, information technology, materials, energy and consumer discretionary, that are relevant to the fund's investment theme of the genomics revolution ("Genomics Revolution Companies"). It is non-diversified.
Consensus and target data currently published for this company.
No generated briefing is available yet.
Yahoo · Oct 10, 2026
The trades put some of Ark's better-known holdings on the sell side, including AMD, Alphabet, and SpaceX, while its genomics-focused ARK Genomic Revolution ETF continued to add to biotech companies.
Benzinga · Sep 18, 2026
Tempus AI stock pulled back Friday but stays firmly above key moving averages. Is the TEM rally still intact? Read more.
Benzinga · Aug 19, 2026
MRK, MRNA's cancer vaccine breakthrough could revive the mRNA trade, putting biotech and genomics ETFs back in focus.
SeekingAlpha · Jul 28, 2026
ARKG remains a Buy as its valuation improves and technical support emerges after a 15% correction from July highs. Learn more about ARKG ETF here.
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning ARKG.
